{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:48:01Z","timestamp":1779929281127,"version":"3.53.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.clinthera.2010.10.004","type":"journal-article","created":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T04:11:28Z","timestamp":1290399088000},"page":"1896-1905","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg\/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: A multicenter, prospective, randomized, double-blind, double-dummy clinical trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Sang-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Joon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Seok","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Dong","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon-Woong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo-Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Su","family":"Hyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Woon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.10.004_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet."},{"key":"10.1016\/j.clinthera.2010.10.004_bib2","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jacc.2008.09.065","article-title":"Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis","volume":"53","author":"Chhatriwalla","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.10.004_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2009.02.017","article-title":"The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis","volume":"31","author":"Delahoy","year":"2009","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.10.004_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1253\/circj.72.17","article-title":"Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: The OACIS-LIPID Study","volume":"72","author":"Sato","year":"2008","journal-title":"Circ J."},{"key":"10.1016\/j.clinthera.2010.10.004_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2010.10.004_bib6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.amjcard.2008.07.023","article-title":"Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)","volume":"102","author":"Johnson","year":"2008","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.clinthera.2010.10.004_bib7","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2007.12.054","article-title":"Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery","volume":"51","author":"Shah","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.10.004_bib8","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.jacc.2006.03.034","article-title":"Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study","volume":"47","author":"Scirica","year":"2006","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.10.004_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation 2004;110:763]","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2010.10.004_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2008.10.029","article-title":"Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus \u226565 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)","volume":"103","author":"Tikkanen","year":"2009","journal-title":"Am J Cardiol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.10.004_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200767001-00005","article-title":"Atorvastatin efficacy in the prevention of cardio-vascular events in patients with diabetes mellitus and\/or metabolic syndrome","volume":"67","author":"Arca","year":"2007","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2010.10.004_bib12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.clinthera.2010.10.004_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.10.004_bib14","series-title":"International monitoring of adverse reactions to drugs: Adverse reaction terminology","year":"1992"},{"key":"10.1016\/j.clinthera.2010.10.004_bib16","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.10.004_bib17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation."},{"key":"10.1016\/j.clinthera.2010.10.004_bib18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.10.004_bib19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4070\/kcj.2006.36.8.593","article-title":"Treatment Gap in the Management of Hypercholesterolemia in Korea; Return on Expenditure Achieved for Lipid TherapY (REALITY)","volume":"36","author":"Kim","year":"2006","journal-title":"Kor Circ J."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810003437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T12:51:27Z","timestamp":1544100687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810003437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0149291810003437"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.10.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}